 | Up a level |
Journal Article
Golfmann, K., Meder, L., Schuldt, P. and Ullrich, R. (2016). The role of FGFR1 signaling in breast cancer to induce tumor angiogenesis. Oncol. Res. Treat., 39. S. 118 - 119. BASEL: KARGER. ISSN 2296-5262
Golfmann, K., Meder, L., Tharun, L., Dietlein, F., Malcher, F., Koker, M., Buettner, R. and Ullrich, R. T. (2017). Targeting FGFR1 and VEGFR1 displays synergistic treatment effects in FGFR1 overexpressed breast cancer. Oncol. Res. Treat., 40. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262
Meder, L., Koenig, K., Dietlein, F., Florin, A., Koker, M., Buettner, R., Heukamp, L. and Ullrich, R. (2018). LIN28B enhanced tumorigenesis in an autochthonous KRASG12V driven lung carcinoma mouse model. Oncol. Res. Treat., 41. S. 291 - 292. BASEL: KARGER. ISSN 2296-5262
Meder, L., Schuldt, P., Thelen, M., Dietlein, F., von Baildon, Bergwelt M., Reinhardt, C. and Ullrich, R. T. (2017). Dual inhibition of anti-VEGF and anti-PD-L1 displays synergistic treatment effects in a small cell lung carcinoma mouse model. Oncol. Res. Treat., 40. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262
Meder, L., Schuldt, P., Vlasic, I, Volz, C., Golfmann, K., Zaplatina, A., Florin, A., Tharun, L., Buettner, R., Reinhardt, C. and Ullrich, R. (2016). Combining anti-VEGF therapy and immune checkpoint inhibitors improves outcome in small cell lung carcinomas. Oncol. Res. Treat., 39. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262
Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C. D., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., Guerreiro, A. da Palma, von Jan, J., Kisis, I., Wasserburger, E., Claasen, J., Faitschuk-Meyer, E., Altmueller, J., Nuernberg, P., Yang, T. -P., Lienhard, M., Herwig, R., Kreuzer, K. -A., Pallasch, C. P., Buettner, R., Schaefer, S. C., Hartley, J., Abken, H., Peifer, M., Kashkar, H., Knittel, G., Eichhorst, B., Ullrich, R. T., Herling, M., Reinhardt, H. C., Hallek, M., Schweiger, M. R. and Frenzel, L. P. (2022). Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood, 140 (20). S. 2113 - 2127. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Volz, C., Zaplatina, A., Siobal, M., Chatterjee, S., Schoettle, J., Meder, L., Florin, A., Koker, M., Buettner, R., Miao, H., Wang, B., Hallek, M., Acker-Palmer, A. S., Heukamp, L. C., Thomas, R. K. and Ullrich, R. (2016). Anti angiogenic treatment induces tumor cell invasion and metastasis via EphA2 signaling in NSCLC. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262